Lundbeck is a Danish specialty pharmaceutical company focused on central nervous system (CNS) disorders including depression, schizophrenia, Parkinson's disease, and migraine. Vyepti (eptinezumab), its CGRP-targeting migraine therapy, is a key growth asset.
Lundbeck plans to relocate its U.S. headquarters from Deerfield, Illinois to Greater Boston, where the Danish neuroscience drugmaker will establish a global innovation hub and expand its artificial intelligence work.
Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy.
Lundbeck received FDA Fast Track designation for Lu AH69593, an investigational orexin-2 receptor agonist being developed for narcolepsy.
Lundbeck hit with untitled letter over Vyepti efficacy claims (Fierce Pharma.)